RE: CLX001 value25 Jun 2025 17:33
Another example:
The largest preclinical oncology license deal is the one between Ipsen and Sutro Biopharma for STRO-003, an antibody-drug conjugate (ADC) targeting the ROR1 tumor antigen, worth up to $1.1 billion. This agreement grants Ipsen exclusive global rights to develop and commercialize STRO-003, which is in the final stages of preclinical development.
Here's a breakdown of the deal:
Partners: Ipsen and Sutro Biopharma.
Drug: STRO-003, an ADC targeting ROR1.
ROR1: A clinically validated target for both solid tumors and hematological malignancies.
Deal Value: Up to $1.1 billion, including upfront payments and milestone-based payments.
Exclusivity: Ipsen secures exclusive worldwide rights.
Preclinical Stage: STRO-003 is in the final stages of preclinical development.